Koo Chang-Hoon, Lee Si Un, Kim Hyeong-Geun, Lee Soowon, Bae Yu Kyung, Oh Ah-Young, Jeon Young-Tae, Ryu Jung-Hee
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Korea.
Korean J Anesthesiol. 2025 Apr;78(2):148-158. doi: 10.4097/kja.24538. Epub 2025 Jan 23.
Maintenance of stable blood pressure (BP) during cerebrovascular bypass surgery is crucial to prevent cerebral ischemia. We compared the effect of remimazolam anesthesia with that of propofol-induced and desflurane-maintained anesthesia on intraoperative hemodynamic stability and the need for vasoactive agents in patients undergoing cerebrovascular bypass surgery.
Sixty-five patients were randomized into remimazolam (n = 31, remimazolam-based intravenous anesthesia) and control groups (n = 34, propofol-induced and desflurane-maintained anesthesia). The primary outcome was the occurrence of intraoperative hypotension. The secondary outcomes included hypotension duration, lowest mean BP (MBP), generalized average real variability (ARV) of MBP, and consumption of phenylephrine, norepinephrine, or remifentanil.
Occurrence rate and duration of hypotension were significantly lower in the remimazolam group (38.7% vs. 73.5%, P = 0.005; 0 [0, 10] vs. 7.5 [1.25, 25] min, P = 0.008). Remimazolam also showed better outcomes for lowest MBP (78 [73, 84] vs. 69.5 [66.25, 75.8] mmHg, P < 0.001) and generalized ARV of MBP (1.42 ± 0.49 vs. 1.66 ± 0.52 mmHg/min, P = 0.036). The remimazolam group required less phenylephrine (20 [0, 65] vs. 100 [60, 130] μg, P < 0.001), less norepinephrine (162 [0, 365.5] vs. 1335 [998.5, 1637.5] μg, P < 0.001), and more remifentanil (1750 [1454.5, 2184.5] vs. 531 [431, 746.5] μg, P < 0.001) than the control group.
Remimazolam anesthesia may provide better hemodynamic stability during cerebrovascular bypass surgery than propofol-induced and desflurane-maintained anesthesia.
脑血管搭桥手术期间维持稳定的血压对于预防脑缺血至关重要。我们比较了瑞马唑仑麻醉与丙泊酚诱导、地氟醚维持麻醉对脑血管搭桥手术患者术中血流动力学稳定性及血管活性药物需求的影响。
65例患者被随机分为瑞马唑仑组(n = 31,基于瑞马唑仑的静脉麻醉)和对照组(n = 34,丙泊酚诱导、地氟醚维持麻醉)。主要结局是术中低血压的发生情况。次要结局包括低血压持续时间、最低平均血压(MBP)、MBP的广义平均实际变异性(ARV)以及去氧肾上腺素、去甲肾上腺素或瑞芬太尼的用量。
瑞马唑仑组低血压的发生率和持续时间显著更低(38.7% 对 73.5%,P = 0.005;0 [0, 10] 对 7.5 [1.25, 25] 分钟,P = 0.008)。瑞马唑仑在最低MBP(78 [73, 84] 对 69.5 [66.25, 75.8] mmHg,P < 0.001)和MBP的广义ARV方面也显示出更好的结果(1.42 ± 0.49 对 1.66 ± 0.52 mmHg/分钟,P = 0.036)。与对照组相比,瑞马唑仑组需要更少的去氧肾上腺素(20 [0, 65] 对 100 [60, 130] μg,P < 0.001)、更少的去甲肾上腺素(162 [0, 365.5] 对 1335 [998.5, 1637.5] μg,P < 0.001),但需要更多的瑞芬太尼(1750 [1454.5, 2184.5] 对 531 [431, 746.5] μg,P < 0.001)。
在脑血管搭桥手术期间,瑞马唑仑麻醉可能比丙泊酚诱导、地氟醚维持麻醉提供更好的血流动力学稳定性。